Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review

Sebastien Barbarot, Natasha K. Rogers, Katrina Abuabara, Helene Aubert, Joanne Chalmers, Carsten Flohr, Jon Hanifin, Luigi Naldi, David J. Margolis, Carle Paul, Matthew J. Ridd, Marie Louise Anna Schuttelaar, Eric Simpson, Marie Tauber, Annika Volke, Stephan Weidinger, Sally R. Wilkes, Andreas Wollenberg, Kim S. Thomas

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Background Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD. Objective We sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD. Methods We conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English. Results In all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application. Limitations We included RCT data only. Conclusion This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

Original languageEnglish (US)
Pages (from-to)1038-1044
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume75
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Atopic Dermatitis
Randomized Controlled Trials
Skin Diseases
Outcome Assessment (Health Care)

Keywords

  • atopic dermatitis
  • atopic eczema
  • flares
  • long-term control
  • outcome measures
  • randomized controlled trials
  • systematic review

ASJC Scopus subject areas

  • Dermatology

Cite this

Barbarot, S., Rogers, N. K., Abuabara, K., Aubert, H., Chalmers, J., Flohr, C., ... Thomas, K. S. (2016). Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. Journal of the American Academy of Dermatology, 75(5), 1038-1044. https://doi.org/10.1016/j.jaad.2016.05.043

Strategies used for measuring long-term control in atopic dermatitis trials : A systematic review. / Barbarot, Sebastien; Rogers, Natasha K.; Abuabara, Katrina; Aubert, Helene; Chalmers, Joanne; Flohr, Carsten; Hanifin, Jon; Naldi, Luigi; Margolis, David J.; Paul, Carle; Ridd, Matthew J.; Anna Schuttelaar, Marie Louise; Simpson, Eric; Tauber, Marie; Volke, Annika; Weidinger, Stephan; Wilkes, Sally R.; Wollenberg, Andreas; Thomas, Kim S.

In: Journal of the American Academy of Dermatology, Vol. 75, No. 5, 01.11.2016, p. 1038-1044.

Research output: Contribution to journalReview article

Barbarot, S, Rogers, NK, Abuabara, K, Aubert, H, Chalmers, J, Flohr, C, Hanifin, J, Naldi, L, Margolis, DJ, Paul, C, Ridd, MJ, Anna Schuttelaar, ML, Simpson, E, Tauber, M, Volke, A, Weidinger, S, Wilkes, SR, Wollenberg, A & Thomas, KS 2016, 'Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review', Journal of the American Academy of Dermatology, vol. 75, no. 5, pp. 1038-1044. https://doi.org/10.1016/j.jaad.2016.05.043
Barbarot, Sebastien ; Rogers, Natasha K. ; Abuabara, Katrina ; Aubert, Helene ; Chalmers, Joanne ; Flohr, Carsten ; Hanifin, Jon ; Naldi, Luigi ; Margolis, David J. ; Paul, Carle ; Ridd, Matthew J. ; Anna Schuttelaar, Marie Louise ; Simpson, Eric ; Tauber, Marie ; Volke, Annika ; Weidinger, Stephan ; Wilkes, Sally R. ; Wollenberg, Andreas ; Thomas, Kim S. / Strategies used for measuring long-term control in atopic dermatitis trials : A systematic review. In: Journal of the American Academy of Dermatology. 2016 ; Vol. 75, No. 5. pp. 1038-1044.
@article{84593c6a428b433b88c9e9375ce0e269,
title = "Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review",
abstract = "Background Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD. Objective We sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD. Methods We conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English. Results In all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91{\%}), use of AD medication (29 RCTs; 28.7{\%}), and AD flares/remissions (26 RCTs; 25.7{\%}). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application. Limitations We included RCT data only. Conclusion This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.",
keywords = "atopic dermatitis, atopic eczema, flares, long-term control, outcome measures, randomized controlled trials, systematic review",
author = "Sebastien Barbarot and Rogers, {Natasha K.} and Katrina Abuabara and Helene Aubert and Joanne Chalmers and Carsten Flohr and Jon Hanifin and Luigi Naldi and Margolis, {David J.} and Carle Paul and Ridd, {Matthew J.} and {Anna Schuttelaar}, {Marie Louise} and Eric Simpson and Marie Tauber and Annika Volke and Stephan Weidinger and Wilkes, {Sally R.} and Andreas Wollenberg and Thomas, {Kim S.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.jaad.2016.05.043",
language = "English (US)",
volume = "75",
pages = "1038--1044",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Strategies used for measuring long-term control in atopic dermatitis trials

T2 - A systematic review

AU - Barbarot, Sebastien

AU - Rogers, Natasha K.

AU - Abuabara, Katrina

AU - Aubert, Helene

AU - Chalmers, Joanne

AU - Flohr, Carsten

AU - Hanifin, Jon

AU - Naldi, Luigi

AU - Margolis, David J.

AU - Paul, Carle

AU - Ridd, Matthew J.

AU - Anna Schuttelaar, Marie Louise

AU - Simpson, Eric

AU - Tauber, Marie

AU - Volke, Annika

AU - Weidinger, Stephan

AU - Wilkes, Sally R.

AU - Wollenberg, Andreas

AU - Thomas, Kim S.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD. Objective We sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD. Methods We conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English. Results In all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application. Limitations We included RCT data only. Conclusion This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

AB - Background Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD. Objective We sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD. Methods We conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English. Results In all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application. Limitations We included RCT data only. Conclusion This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

KW - atopic dermatitis

KW - atopic eczema

KW - flares

KW - long-term control

KW - outcome measures

KW - randomized controlled trials

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=84982895271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982895271&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2016.05.043

DO - 10.1016/j.jaad.2016.05.043

M3 - Review article

C2 - 27522613

AN - SCOPUS:84982895271

VL - 75

SP - 1038

EP - 1044

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 5

ER -